Sang Taek Kim, MD, PhD
Assistant ProfessorCards
About
Research
Publications
2024
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune checkpoint inhibitor therapyAnti-IL-17A antibodyAdverse eventsAnti-PD-1 antibody monotherapyInterleukin (IL)-17/IL-23 axisPsoriatic arthritisImmune checkpoint inhibitor treatmentPD-1 antibody therapyResponse to ICI therapyImmune-related adverse eventsIL-23/IL-17 axisImmune checkpoint inhibitor exposureIL-17/23 axisAnti-CTLA-4Checkpoint inhibitor therapyCell renal cell carcinomaAnti-IL-17AAnti-IL-23 antibodyAssociated with adverse eventsPre-existing psoriasisAnti-tumor efficacyIL-23/IL-17Renal cell carcinomaICI therapyAuthor Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.Peer-Reviewed Original ResearchEmerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerFollicular-derived thyroid cancersAdvanced thyroid cancerThyroid cancerFood and Drug AdministrationManagement of advanced thyroid cancerEra of immunotherapyTargeted kinase inhibitorsU.S Food and Drug AdministrationImmune milieuRefractory diseaseExcellent prognosisTherapeutic optionsTreatment optionsKinase inhibitorsDrug AdministrationGenetic driversTherapeutic avenuesCancerImmunotherapyGenetic landscapeRadioiodineTreatmentMolecular basisOptionsThe Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte-Baran W, Kim S. The Current and Future of Biomarkers of Immune Related Adverse Events. Rheumatic Disease Clinics Of North America 2024, 50: 201-227. PMID: 38670721, PMCID: PMC11232920, DOI: 10.1016/j.rdc.2024.01.004.Peer-Reviewed Original Research
2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsGround-glass opacitiesBlood biomarkersImmune checkpoint inhibitor pneumonitisCheckpoint inhibitor pneumonitisAcute myeloid leukemiaPost-test probabilityCheckpoint inhibitorsMyeloid leukemiaCT patternsLung inflammationPneumonitisInfected lungsRelevant blood biomarkersDiagnostic valueLung parenchymaPneumoniaCT imagesBloodBiomarkersPatientsHabitat imagesBlood modelDetection of pneumoniaLeukemiaLearning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune-related adverse eventsPre-existing autoimmune diseaseAutoimmune diseasesCheckpoint inhibitorsFlare-upBenefit of immune checkpoint inhibitorsAutoimmune disease flare-upManagement of flare-upsPre-existing autoimmune disordersImmune checkpoint inhibitor treatmentCancer CenterDisease flare-upContext of autoimmune diseasesAutoimmune disease progressionAutoimmune disease treatmentAutoimmune disordersAdverse eventsTreatment modificationOrgan damageComprehensive cancer centerDisease progressionPatientsCancerUS cancer centersPneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer
Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Clavijo C, Shannon V, Faiz S, Gandhi S, Lin S, Lopez P, Zhong L, Akhmedzhanov F, Godoy M, Shroff G, Wu J, Khawaja F, Kim S, Naing A, Heymach J, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer. Clinical Oncology 2023, 35: 630-639. PMID: 37507279, DOI: 10.1016/j.clon.2023.07.003.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitionLA-NSCLCCell lung cancerInterstitial lung diseaseCheckpoint inhibitionLung cancerLung diseaseRisk factorsMultivariate Cox proportional hazards modelAssociated with higher all-cause mortalityLA-NSCLC patientsMean radiation doseHazards modelMultivariable cause-specific hazards modelRetrospective chart reviewCox proportional hazards modelsAll-cause mortalityProportional hazards modelCombined chemoradiationConcurrent chemoradiationMedian ageCause-specific hazard modelA Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept
Ostrin E, Rider N, Alousi A, Irajizad E, Li L, Peng Q, Kim S, Bashoura L, Arain M, Noor L, Patel N, Mehta R, Popat U, Hosing C, Jenq R, Rondon G, Hanash S, Paczesny S, Shpall E, Champlin R, Dickey B, Sheshadri A. A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of Concept. ImmunoHorizons 2023, 7: 421-430. PMID: 37289498, PMCID: PMC10491477, DOI: 10.4049/immunohorizons.2300031.Peer-Reviewed Original ResearchConceptsBronchiolitis obliterans syndromeHematopoietic cell transplantationGraft-versus-host diseaseHematopoietic cell transplant recipientsTransient impairmentCell transplantationNasal inflammationNew-onset bronchiolitis obliterans syndromeChronic graft-versus-host diseaseMultiplex magnetic bead immunoassayNasal mucosal lining fluidAllogeneic hematopoietic cell transplantationMucosal lining fluidInflammatory cytokine signatureType 2 inflammationT cell activationMagnetic bead immunoassayNasal inflammatory responseRespiratory tract inflammationCounterregulatory moleculesBetween-group differencesIL-17ACytokine signatureBead immunoassayClinical criteriaSarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
Soto F, Torre-Sada L, Mott F, Kim S, Nurieva R, Nagarajan P, Guo M, Shannon V, Faiz S, Casal R, Altan M, Lin J, Sheshadri A. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature. Journal Of Immunotherapy And Precision Oncology 2023, 6: 111-116. PMID: 37214206, PMCID: PMC10195014, DOI: 10.36401/jipo-22-30.Peer-Reviewed Original ResearchImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyInhibitor therapyPulmonary toxicityEosinophilic asthmaAirway diseaseImmune related adverse eventsPD-1 inhibitor pembrolizumabSevere eosinophilic asthmaRelated adverse eventsICI therapyInhibitor pembrolizumabPD-1Benign courseTreatment cessationFatal complicationCase reportAdverse eventsSarcoidosisTherapyPneumonitisAirwayPatientsToxicityAsthma
2022
Rheumatology (Arthritis and Myositis)
Kim S, Bowman S, Lu H. Rheumatology (Arthritis and Myositis). 2022, 301-313. DOI: 10.1007/978-3-031-00241-0_15.Peer-Reviewed Original ResearchImmune-related adverse eventsRheumatic immune-related adverse eventsImmune checkpoint inhibitorsAssociated with immune checkpoint inhibitorsDiscontinuation of immune checkpoint inhibitorsSystemic immune-related adverse eventsCourse of treatmentCheckpoint inhibitorsMyositis symptomsPersistent inflammatory arthritisComplete resolutionAdverse eventsRegistry studyInflammatory arthritisPrevalent typeMyositisPatientsArthritisArticularImmunosuppressionDMARDsArthralgiaMyalgiaPolymyalgia
Clinical Care
Overview
Sang Taek Kim, MD, PhD, is a rheumatologist who cares for people with autoimmune conditions that affect the joints, muscles, bones, and other organs. He treats conditions including rheumatoid arthritis, lupus, psoriatic arthritis, gout, and vasculitis.
Dr. Kim offers a range of therapies to help relieve pain, reduce inflammation, and improve mobility and quality of life. In particular, he is experienced in managing rheumatology patients with preexisting or coexisting cancers.
Dr. Kim investigates how cancer immunotherapy can cause autoimmune complications, known as immune-related adverse events (irAEs). He works to develop optimal strategies for managing irAEs without compromising the efficacy of cancer immunotherapy.
Dr. Kim received his medical training from Yonsei University College of Medicine in South Korea. After completing his internal medicine training at Mount Sinai Hospital, he completed a rheumatology fellowship at Yale School of Medicine.
Clinical Specialties
Rheumatology; Internal Medicine
News
News
- May 02, 2025
Immunotherapy: Balancing Cancer Treatment Benefits and Risks
- November 13, 2023
Sang Taek Kim Returns to YSM to Lead Immunotherapy Adverse Events Program
- November 08, 2023
Yale Advances Rheumatology Research and Practice at American College of Rheumatology Convergence 2023
- August 16, 2023
Welcome New Postdocs, Postgrads, Fellows, Faculty & Staff! (August 2023)